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ABSTRACT
Pulmonary thromboembolism (PTE) is one of the major complications in oncologic patients. The incidence of PTE in these 
cases is 4 to 7 times higher than in non-oncologic patients. Ovarian tumors, specifically those of large sizes, may impair 
the blood flow through the pelvic veins as tumor pressure over the pelvic vessels increases the incidence of thrombosis. 
The authors report the case of the unexpected death of a 74-year-old female due to massive pulmonary thromboembolism, 
associated with an ovarian tumor almost of 15 kg of weight that filled the abdominal and pelvic cavities. The compressive 
effect on the walls of the pudendal and periuterine veins somehow facilitated the local thrombosis. According to the 
histological characterization on post-mortem samples, the mass was identified as an “atypical proliferative (borderline) 
mucinous tumor.” The case emphasizes the important association between pulmonary thromboembolism and ovarian 
tumors
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INTRODUCTION
Deep vein thrombosis (DVT) and pulmonary 
thromboembolism (TEP) are severe1 and frequent2 
complications (42%) in women with advanced 
ovarian neoplasms,1-4 large uterine fibromas5 and 
in patients undergoing chemotherapy.6 In patients 
with large solid malignancies, besides the mechanism 
triggered by the immunologic, inflammatory and the 
released substances related to the tumor response, the 
pressing on the large vessels such as the inferior vena 
cava, pelvic and iliac veins may result in bloodstream 
stasis, turbulent flow and vessels injury, increasing 
the probability for thombosis.7 Among all abdominal 
and pelvic tumors in women, ovarian neoplasms 
represent the main cause of pulmonary embolism and 
thrombophlebitis.8,9
The WHO classification of 2014 divides the 
surface epithelial tumors of the ovary into benign, 
borderline and malignant and the different histological 
types into serous, mucinous, endometrioid, clear 
cells, Brenner and seromucinous.10 Borderline ovarian 
tumors are characterized by a smaller aggressiveness 
when compared with other epithelial forms11 and 
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are currently defined “atypical proliferative epithelial 
tumors.” This type of tumor usually occurs in the third 
or fourth decade and is unilateral in 80% of cases.12 
According to the tumor biology and behavior, the 
prognosis is usually favorable, but life-threatening 
outcomes may be observed by the compression on the 
surrounding structures when the tumor reaches large 
dimensions, leading to unexpected death.
In this context, the main goal of this case report 
is to emphasize the important association between 
pulmonary thromboembolism and ovarian tumors of 
such greatness.
CASE REPORT
A 74-year-old female who lived alone was found 
dead in her home. The estimated time of death was 
evaluated to be of 48 hours. According to the relatives’ 
information, she was diagnosed with hypertension and 
was under a diagnostic workup of an ovarian cyst. 
The judicial authority required an autopsy, which was 
performed 2 days after the discovery of the corpse.
Autopsy Presentation
The external examination revealed an apparent 
well-preserved corpse with a body mass index of 34.8, 
without any sign of external injuries. The examination 
of the head and neck was unremarkable. However, 
the examination of the lung depicted an extensive 
bilateral thrombosis of the main pulmonary arteries 
until their segmental subdivision. The large thrombus 
entirely occluded the arterial lumen, reproducing the 
shape of the vessel as a “cast”, coated by the intimal 
surface, characterizing a bilateral massive pulmonary 
thromboembolism.
According to the morphological characteristics, 
a thromboembolic nature was macroscopically 
confirmed (Figures 1 and 2).
At the opening of the abdominal and pelvic 
cavities, the left uterine adnexa were represented by 
a smooth cystic tumor, weighing 15 kg (Figure 3) and 
measuring 33 cm in its longest axis. At the cut surface, 
the cyst was multiloculated and drained a yellowish 
mucinous material. No papillary excrescences were 
seen, but a partly necrotic and solid nodule of 8.5 cm 
was found adhered to the cystic wall.
The examination of the contralateral ovary and 
uterus was unremarkable, the latter showing an 
atrophic endometrium. The bilateral dissection of 
the deep vessels of the lower limbs failed to show 
thrombosis, while the exploration of the veins of the 
pudendal plexus (ovarian and periuterine veins) showed 
the presence of extensive thrombosis (Figure 4).
No other noteworthy finding was detected. 
The cause of death was identified as massive pulmonary 
thromboembolism in a woman with a large ovarian 
neoplasm. During the autopsy, different organs were 
sampled (uterus, ovarian neoplasm, pudendal plexuses 
and thrombotic formations) for histopathologic 
investigation.
Figure 1. Macroscopic view of the thromboembolic events. A – Gross view of the thrombus in the pelvic vessels; 
B – Gross view of pulmonary thromboembolism.
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Moreover, samples of biological fluids (heart 
and femoral blood, urine, bile and gastric content) 
were taken for toxicological analyses. The search for 
drugs and/or alcohol was performed and results were 
negative.
Microscopically, the massive ovarian neoplasm 
was assessed as “atypical proliferating mucinous tumor 
(borderline)” (Figure 5) and the thrombotic nature of 
the occluding material in the periuterine veins was 
confirmed, with secondary thromboembolism in the 
pulmonary arteries.13
Therefore, the cause of death was identified as 
pulmonary thromboembolism due to pelvic thrombosis, 
concomitant with a giant ovarian neoplasm. According 
to the evidence provided by the autopsy and the 
histological findings, the compression effect of the 
mass on the pudendal venous plexus enabled the 
formation of intravascular thrombi, whose detachment 
led to pulmonary embolism and death.
Figure 2. Photomicrograph of thrombosis of a pelvic 
vein (Masson’s trichrome staining: 200 X).
Figure 3. Macroscopic examination of the ovarian tumor. A – Gross view of the tumor, after the abdominal cavity 
overture; B – Macroscopic view of the tumor external wall; C – Inner surface view with the multiple cystic formations 
of varying sizes; D – Cut surface of the solid nodule adhered to the cystic wall.
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DISCUSSION
In 1865, Trousseau14 described the correlation 
between tumors and venous thrombosis, and since 
then, neoplasms have been recognized as a risk factor 
for venous thromboembolism (VTE) and, consequently, 
pulmonary embolism (PE).15 The Virchow classic triad 
of endothelial damage, hypercoagulability and venous 
stasis is considered to be the mechanism responsible 
for the pathogenic onset.16 The Trousseau syndrome 
(tumor-associated thrombosis) is the second cause of 
death in oncologic patients after the progression of the 
disease itself.17 The risk of pulmonary embolism in this 
group of patients is 4 to 7 times higher if compared 
to non-neoplastic patients.4,17
Previous studies18 report thrombotic events in 
20% of patients with malignancy18 and up to 20% 
of these patients will present embolic events.19 Some 
neoplasms, especially pancreatic and gastrointestinal,20 
are associated with higher rates of thrombosis.15,21 
Other neoplasms of the peritoneal and pelvic cavities 
(i.e., endometrial or bladder tumors) and, in particular, 
ovarian and extrahepatic biliary ducts are usually 
linked to high incidence of pulmonary embolism.22,23 
In particular, the highest prevalence of pulmonary 
embolism and thrombophlebitis has been witnessed 
in neoplastic ovarian patients,8 especially among 
germinal types.24 This is due to the combination 
of the pelvic blood flow obstruction by the mass,7 
the effect of estrogen hormone treatment25 and 
the overexpression of the tissue factor associated 
with high D-dimer levels, which is considered to 
be an important factor in hypercoagulability.26 
The coagulation cascade activation and the embolic 
events occur in association with neoplasms because of 
the tissue factor (TF) and cancer procoagulant (CP).27 
Moreover, a crucial role may be played by inflammatory 
cytokines and the relationship between neoplastic cells, 
monocytes, macrophages, platelets and endothelial 
cells. Inaddition, thrombosis may be favored by 
chemotherapy, hormone therapy or radiotherapy. 
Other mechanisms that also may take part in thrombus 
formation are related to the relationship between the 
host and the tumor (i.e., acute phase inflammation, 
Figure 5. In A, residual papillary structure of epithelium with multilayer cores (EE: 200X, in B higher magnification 
EE: 1000X), with evidence of moderate nuclear atypia. In C (periodic acid-Schiff stain, 32X) and D (Alcian blue 
pH 2.5,100X), high amount of mucus tightly fixed to the internal surface of neoformation.
Figure 4. Macroscopic examination of the thrombosis 
of the pudendal plexus sample in three different regions 
of the plexus.
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angiogenesis), decreased inhibitors of coagulation and 
impaired fibrinolysis.28,29
It is evident that the development of the neoplasm 
highlights the importance of therapeutic choices, 
even in the case of benign neoplasms, along with 
the analysis and characterization of the social and 
cultural conditions of the patient. This case confirms 
what is reported in the literature30,31 about the 
association between pulmonary embolism and 
epithelial neoplasms.
CONCLUSION
The presented case is peculiar because a sudden 
death occurred from complications related to ovarian 
neoplasm, with increased predisposition to deep 
venous thrombosis.
According to Italian Law, all the material sampled 
during a Judicial Autopsy does not require any 
authorization by the family members of the deceased 
to be studied and published, except with the precaution 
of maintaining the anonymity of the patient.
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